03.12.18
Alastin Skincare, Inc. has appointed Ann Rhoads and Elisabeth Sandoval to the company's board of directors.
Rhoads is a healthcare finance executive with more than 25 years of experience which includes roles as CFO of two companies, raising over $400M through public and private offerings, and service as a board director and chair of audit and compensation committees across several public and private boards. In addition to her operating roles in healthcare companies, she has experience as an executive with the VC firm Sprout Group, and the management consulting firm Bain & Company.
Sandoval holds a proven track record of successful business leadership and development of leading brands in a variety of areas including the medical aesthetics arena. She currently serves as chief commercial officer for Alder Biopharmaceuticals, and previously was chief commercial officer at Kythera Biopharmaceuticals, which was sold to Allergan in 2015 for $2.1 billion. Prior to this, Sandoval spent 24 years at Allergan Inc., where she held the role of vice president, global strategic marketing, and drove the launch of the market-leading Juvederm dermal filler and established its worldwide marketing team.
“We are extremely pleased to have Ann and Elisabeth join the ALASTIN team on our Board of Directors,” said Diane S. Goostree, president and CEO of Alastin Skincare. “They bring a wealth of experience related to financial and commercialization strategies within the healthcare and aesthetics space and will be valuable advisors to us as we continue our rapid growth and evolution as a leader in the aesthetics field with our Procedure Enhancement System products and daily skin care Restore & Renew product line.”
Rhoads is a healthcare finance executive with more than 25 years of experience which includes roles as CFO of two companies, raising over $400M through public and private offerings, and service as a board director and chair of audit and compensation committees across several public and private boards. In addition to her operating roles in healthcare companies, she has experience as an executive with the VC firm Sprout Group, and the management consulting firm Bain & Company.
Sandoval holds a proven track record of successful business leadership and development of leading brands in a variety of areas including the medical aesthetics arena. She currently serves as chief commercial officer for Alder Biopharmaceuticals, and previously was chief commercial officer at Kythera Biopharmaceuticals, which was sold to Allergan in 2015 for $2.1 billion. Prior to this, Sandoval spent 24 years at Allergan Inc., where she held the role of vice president, global strategic marketing, and drove the launch of the market-leading Juvederm dermal filler and established its worldwide marketing team.
“We are extremely pleased to have Ann and Elisabeth join the ALASTIN team on our Board of Directors,” said Diane S. Goostree, president and CEO of Alastin Skincare. “They bring a wealth of experience related to financial and commercialization strategies within the healthcare and aesthetics space and will be valuable advisors to us as we continue our rapid growth and evolution as a leader in the aesthetics field with our Procedure Enhancement System products and daily skin care Restore & Renew product line.”
